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Abstract  
Introduction: Cardiovascular disease, especially coronary and cerebral, is the leading cause 
of death in diabetic patients. The aims of our study were to investigate carbohydrate 
metabolism disorders in patients with stroke, to analyze factors influencing stroke prognosis 
and to study the relationship between plasma glucose levels at admission and mortality rate 
after 14 days from the acute event in those patients. 
Materials and Method: For this study we enrolled 208 subjects diagnosed with stroke. For 
all subjects plasma glucose level at admission and after 14 days from admission was 
measured. We investigated the relationship between glycemia at admission and mortality rate 
respectively glycemia after 14 days. 
Results and discussion: From all patients involved in the study 31 had Type 2 Diabetes 
Mellitus (T2DM). In the patients group without previously diagnosed T2DM, 19 had plasma 
glucose level at admission > 125 mg/dL, 12 between 110-125 mg/dL and 146 below 110 
mg/dL. In the group of patients not previously diagnosed with diabetes having plasma 
glucose level > 125 mg/dL at admission, 66.7% still had plasma glucose >125 mg/dL after 14 
days from admission. We found a positive correlation between plasma glucose level at 
admission and mortality caused by stroke. 
Conclusions: T2DM is a major risk factor for stroke. Plasma glucose level at admission was 
correlated positively with stroke mortality, both in patients with T2DM and in those without 
previously diagnosed T2DM, independently of other related factors. 
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Introduction 
Atherosclerosis is the dominant etiologic factor for stroke. Cardiovascular disease, 
involving atherosclerosis, especially coronary and cerebral, as its morphophatologic substrate 
is the leading cause of death for T2DM patients. 
 Elevated blood glucose is common in the early phases of stroke. Although up to one 
third of acute stroke patients had either been diagnosed or newly diagnosed with diabetes, 
probably a major proportion of patients having stress hyperglycemia mediated partly by the 
release of cortisol and norepinephrine. It is also an outcome of relative insulin deficiency, 
which is associated with increased lipolysis. Even in nondiabetic patients, stress 
hyperglycemia may be a marker of defective glucose regulation in individuals with insulin 
resistance and developing T2DM (Perttu, 2004). 
 Experimental studies have demonstrated that hyperglycemia contributes to brain 
damage through different mechanisms: increasing blood brain permeability, producing 
cerebral edema, and promoting the release of inflammatory mediators (Garg, 2006; 
Marquardt, 2005; Godoy, 2010). An additional mechanism of injury, ischemia, is mediated 
by vasoconstriction and thrombosis in microcirculation (Garg, 2006; Godoy, 2010). 
 The prognostic value of hyperglycemia has been extensively evaluated; however, to 
date, it is not clear whether hyperglycemia contributes directly to worsen the outcome, or 
whether it just represents a surrogate marker of the stroke’s severity (Garg, 2006; McCowen, 
2001; Godoy, 2010). The management of hyperglycemia in this setting is still controversial 
and varies worldwide (Godoy, 2010; McCormick, 2008). 
 Blood glucose is usually increased immediately after the stroke, probably being the 
result of stress response to the stroke event (Yong, 2008; Allport, 2006; Gray, 2007; Walters, 
2006). However, within at least a week, blood glucose usually declines and reaches a stable 
level (Allport, 2006; Gray, 2007; Walters, 2006; Szczudlik, 2001). Most studies are 
suggesting that an association between initial stroke severity and hyperglycemia on 
admission exists (Jørgensen, 1994; Wong, 2008; Stead, 2009). Fasting blood glucose (FBG) 
measured about one week after stroke (when the stress response has resolved) (Szczudlik, 
2001) represents the patient’s habitual blood glucose at the time of the stroke. 
The aims of our study were to investigate carbohydrate metabolism disorders in 
patients with stroke, to analyze factors influencing stroke prognosis and to study the 
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relationship between plasma glucose levels at admission and mortality rate after 14 days from 
the acute event in those patients. 
Main Text 
Materials and Method 
 Study population: We conducted a hospital-based study, lasting one year, from 
January to December 2012, at the Neurology Department of the Timisoara Emergency 
Clinical Country Hospital. 
The participants were selected from patients hospitalized in the Neurology 
Department, all of them admitted for an acute stroke event. The study protocol was approved 
by the ethics committee of the Timisoara Emergency Clinical Country Hospital, and the 
participants signed their informed consent at the time of recruitment. The study enrolled 208 
subjects diagnosed with stroke, 16 (7.69%) hemorrhagic stroke and 192 (92.31%) with 
ischemic stroke, 52.7% men and 48.3% women, having an average age 57.2± 6.9. 
Laboratory data: The venous blood samples were collected in the morning, after 12 
hours of fasting. In all participants, FBG was measured at admission, and at 14 days from 
admission. 
The diagnosis of stroke was established based upon neurological examination and 
laboratory investigation (including CT-scan and/or MRI). We investigated the relationship 
between admission glycemia and mortality rate respectively glycemia after 14 days. 
Statistical methods: All patient data were summarized in the electronic health record. 
The mortality rate is expressed as a number of deceases per 100 patients in the studied 
interval. Fisher’s exact test was used for assessing the significance level of differences 
between proportions (p value below 0.05 was considered to be significant). To evaluate the 
association between a factor and an outcome, odds ratio (OR) indicator was used, along with 
its 95% confidence interval (CI) and statistical significance. 
Results 
 From the total of 208 patients diagnosed with stroke, 31 were previously diagnosed 
with T2DM. In the previously undiagnosed patients (177), 19 individuals (10.73%) had 
glycemic values at admission over 125 mg/dL; 12 (6.78%) had glycemic values between 110 
- 125 mg/dL and 146 (82.49%) had normal glycemic values (<110 mg/dL), Figure 1. 
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Figure 1. Plasma glucose levels at admission 
 
 In the entire group, the mortality rate at 14 days after admission was 10.1% (21 
patients). The highest mortality rate was found in patients not previously diagnosed with 
T2DM but which had plasma blood glucose levels higher than 125 mg/dL. The group of 
patients having admission glycemia between 110-125 mg/dL had a 14 day mortality rate of 
16.6 %, which was similar to the one found in previously diagnosed T2DM patients 
(16.13%). A significant decreased mortality rate was found in patients not diagnosed with 
T2DM which had glycemic values under 110 mg/dL (6.84%), Figure 2. 
Figure 2. Mortality rates at 14 days after admission in patients with stroke. 
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We found an increased risk for decease (related to the group with glycemic values at 
admission <110 mg/dL) in all the other three studied groups. While significant increases in 
risk of death were found only in the group with plasma blood glucose levels higher than 125 
mg/dL, the other two groups had increases but these rises in OR were not significantly 
statistical (Table 1). 
Table 1. ODDS RATIO vs. not previously diagnosed group and with 
plasma blood glucose at admission below 110 mg/dL 
ODDS RATIO for decease 
(95 % CI)  
Patients previously diagnosed with DM 2.62 (0.83 – 8.28); p=0.102 
Patients not diagnosed with 
T2DM prior admission 
Glycemia at admission >125 3.63 (1.01 – 12.99); p=0.048 
Glycemia at admission: 110-125 2.72 (0.52 – 14.14); p=0.23 
 
The repeated measurement of plasma glucose levels after 14 days from admission 
revealed that 66.7% (10 individuals out of 15 survivors) from the patients with initial 
glycemia higher than 125 mg/dL had also a glycemia higher than 125 mg/dL at the repeated 
measurement, the patients being now diagnosed with T2DM. 
Discussion 
Studies are revealing that even in the normal range of FBG there is a significant 
association between more severe strokes and higher FBG one week after the stroke. Because 
blood glucose was measured at a time when the stress-induced blood glucose was increased 
(Yong, 2008; Allport, 2006; Gray, 2007; Walters, 2006; Wong, 2008) event which had been 
resolved after 14 days from the acute event (Jørgensen, 1994; Wong, 2008; Stead, 2009), our 
study points to a significant association between higher glucose concentrations and more 
severe stroke-induced brain injury. 
Most studies indicate a direct association between stroke severity and blood glucose 
concentrations at stroke onset (Yong, 2008; Jørgensen, 1994; Capes, 2001; Weir, 1997; 
Bruno, 1999; Kamouchi, 2011; Putaala, 2010). Blood glucose measured at that time cannot 
be assumed to reflect the patient’s habitual blood glucose prior stroke onset (Rehncrona, 
1981). At one week after the stroke, FBG concentrations have declined, stabilized, and the 
FBG concentration may then reflect the patient's habitual blood glucose concentration at the 
time of the stroke (Szczudlik, 2001). We consider this the most likely explanation for the 
strong association between stroke severity and FBG at one week after the event, seen in our 
study. 
There is compelling experimental and clinical evidence of an association between 
hyperglycemia and poorer outcome after stroke (Yong, 2008; Jørgensen, 1994; Capes, 2001; 
Weir, 1997; Bruno, 1999; Kamouchi, 2011; Putaala, 2010). Our study now provides clinical 
evidence that indicates: higher FBG concentrations even within the normoglycemic range are 
European Scientific Journal    April 2013 edition vol.9, No.12    ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
137 
 
also associated with poorer outcome. This statement agrees with numerous animal studies 
which revealed a toxic effect of higher glucose concentrations in ischemic brain tissue, in 
particular those demonstrating glucose as the substrate for lactate production in the ischemic 
penumbra (Dietrich, 1993; De Courten-Myers, 1992; De Courten-Myers, 1989; Prado, 1988; 
Kawai, 1997). 
Due to the encouraging results of the treatment regimens that used tight glucose 
control in the management of the critically ill patients (Van Den Berghe, 2001; Malmberg, 
1995; Pittas, 2006), the current guidelines are recommending the lowering of blood glucose 
at least if it is high at admission (Kreisel, 2010). To date, the GIST-UK trial (Gray, 2007) is 
the only completed randomized study which analyses the glucose-lowering therapy in stroke. 
This trial’s main aim was to determine whether treatment with glucose-potassium-insulin 
infusion for 24 hours, used in order to maintain normoglycemia within the range of 70–130
mg/dL, might reduce the mortality or the severe disability at 90 days after the stroke. The 
result of this study was negative; the investigators haven’t found any evidence of insulin’s 
treatment beneficial effect on reducing mortality or disability after stroke, and safety 
concerns were raised since a number of patients required rescue intravenous glucose 
treatment because hypoglycemic episodes occurred. However, the treatment was initiated in 
average after 13 hours from the stroke, at a time when most irreversible brain damage already 
had taken place. Hence, the negative outcome of the study is not excluding that higher blood 
glucose, at the time of stroke, may increase brain damage and initial stroke severity. 
Conclusion 
Our study provides clinical evidence regarding an association between more severe 
strokes and higher blood glucose even within the normoglycemic range following stroke. 
This recent evidence supports that acute, elevated, predominantly stress-related 
hyperglycemia is associated with poor outcomes. Through several different biochemical 
mechanisms, elevated glucose in the setting of cerebrovascular injury probably accelerates 
the course of ischemic damage, also in the boundary regions having milder perfusion deficit. 
However, obtaining normoglycemia as soon as possible should be encouraged, although 
conclusive evidence of decreased risk with this approach is lacking. Especially the 
nondiabetic patients may be at risk of further brain damage if hyperglycemia prevails. 
T2DM is a major risk factor for stroke. Measuring the plasma glucose levels is 
mandatory at admission and should be repeated at least once more before discharge, in all 
patients with stroke. Plasma glucose levels at admission are correlated positively, both in 
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patients with T2DM and those without previously diagnosed DM with the mortality after 
stroke, independently of other factors. 
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